8-K: Protalix Reports Mixed Q3, Strong YTD Revenue Growth

Protalix BioTherapeutics announced its third quarter 2025 financial results, showing a 24% year-to-date revenue increase despite a slight Q3 dip, alongside key pipeline advancements and a European regulatory challenge for Elfabrio.

Summary

• Total revenues for the first nine months of 2025 increased by 24% to $43.6 million compared to the same period in 2024.
• Total revenues for the third quarter of 2025 were $17.9 million, a 1% decrease compared to the third quarter of 2024.
• Net income for Q3 2025 was approximately $2.4 million, or $0.03 per share, down from $3.2 million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, improved to approximately $1.1 million, or $(0.01) per share, from a $3.6 million net loss in the same period of 2024.
• Research and development expenses increased by 50% in Q3 2025 to $4.5 million and by 58% year-to-date to $13.9 million, primarily due to preparations for the PRX-115 Phase 2 clinical trial.
• An Investigational New Drug (IND) application for PRX-115, a candidate for uncontrolled gout, became effective in October 2025, with a Phase 2 trial planned for later this year.
• Chiesi Global Rare Diseases, in collaboration with Protalix, requested a re-examination of a negative opinion from the European Medicines Agency's CHMP regarding a new 2 mg/kg every 4 weeks dosing regimen for Elfabrio.
• The currently approved 1 mg/kg every 2 weeks dosing regimen for Elfabrio in the EU remains unaffected.
• As of September 30, 2025, the company had $29.4 million in cash and cash equivalents and short-term bank deposits, believed to be sufficient for at least 12 months.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. Strong year-to-date revenue growth and significant progress with the PRX-115 pipeline are key positives. However, the slight dip in Q3 revenues and net income, coupled with the European regulatory hurdle for Elfabrio's dosing regimen, introduce some caution. The company's cash position is stable for the near term.

Positives

• Year-to-date total revenues increased by 24% to $43.6 million, demonstrating strong commercial success of enzyme replacement therapies.
• Net loss for the first nine months of 2025 significantly improved to $1.1 million from $3.6 million in the prior year period.
• The Investigational New Drug (IND) for PRX-115 for uncontrolled gout became effective in October 2025, with a Phase 2 clinical trial planned to initiate later this year, indicating pipeline advancement.
• Encouraging first-in-human data for PRX-115 suggests potential as a best-in-class, long-acting therapy.
• The company's cash and cash equivalents and short-term bank deposits of $29.4 million are deemed sufficient to satisfy capital needs for at least 12 months.
• A tax benefit of approximately $0.1 million was recorded in Q3 2025, partly due to the restoration of deductibility for domestic research expenditures under the new HR1 tax reform.

Negatives

• Total revenues for the third quarter of 2025 decreased by 1% to $17.9 million compared to the same period in 2024.
• Net income for the third quarter of 2025 decreased by 25% to $2.4 million from $3.2 million in Q3 2024.
• The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion in October 2025 regarding a proposed 2 mg/kg every 4 weeks dosing regimen for Elfabrio.
• Research and development expenses increased significantly by 50% in Q3 2025 and 58% year-to-date, which will continue to be substantial as clinical trials advance.

Risks

• Risks related to the commercialization of Elfabrio, including market acceptance, competition, reimbursement, and regulatory actions (e.g., boxed warning).
• Possible disruption of operations due to military actions in Israel and the broader region, potentially affecting regulatory authorities, suppliers, partners, clinical trial sites, distributors, and customers.
• Risks related to the regulatory approval and commercial success of other product candidates, if approved.
• Failure or delay in the commencement or completion of preclinical studies and clinical trials due to factors like slow patient recruitment, unforeseen safety issues, dosing issues, or lack of effectiveness.
• Delays in the approval or potential rejection of applications with health regulatory authorities, including the re-examination request for Elfabrio's proposed dosing regimen.
• Adverse impacts from global conditions such as new tariffs, trade restrictions, supply chain challenges, inflation, tight labor markets, and banking industry instability.
• Risks related to the need to raise additional capital through public or private equity or debt markets.
• The risk that clinical trial results will not support safety or efficacy claims, or that product candidates will have undesirable side effects.
• Risks relating to the ability to manage relationships with collaborators, distributors, or partners, including Pfizer and Chiesi.
• Risks relating to changes to interim, top-line, or preliminary data from clinical trials.
• Risks concerning the compliance by Fundão Oswaldo Cruz (Fiocruz) with its purchase obligations, which could lead to agreement termination.
• Risk of significant lawsuits, including stockholder litigation.
• Dependence on third-party providers for services and supplies.
• The impact of development of competing therapies and/or technologies by other companies.
• Potential product liability risks and risks of securing adequate insurance coverage.
• The possibility of infringing third-party patents or other intellectual property rights and the uncertainty of obtaining and enforcing intellectual property rights.
• Risks relating to changes in healthcare laws, rules, and regulations.

Future Outlook

The company expects to continue incurring significant research and development expenses as it advances preclinical and clinical trials, including the planned initiation of the Phase 2 clinical trial for PRX-115 and the development of additional research stage programs. Minimal revenues from license and R&D services are expected now that Elfabrio's clinical development is complete, aside from potential regulatory milestone payments.

Management Comments

• "We are pleased to report total revenues of $43.6 million for the first nine months of 2025, an increase of 24%, compared to the same period in 2024. Our total revenues for the third quarter were $17.9 million which reflects a decrease of 1%, compared to revenues for the same period of 2024."
• "We recognize revenues from sales of our products to Chiesi, Pfizer, and Fiocruz in Brazil, and their purchases vary from quarter to quarter as they control their own inventories. Overall, these revenues reflect the continued commercial success of our enzyme replacement therapies and provide a strong foundation to support our research and development efforts."
• "We are particularly excited about PRX-115, our recombinant PEGylated uricase candidate under development for the treatment of uncontrolled gout, which we believe has the potential to be a differentiating treatment for uncontrolled gout... Based on encouraging first-in-human data from our phase 1 clinical trial of PRX-115, we believe it has the potential to be a best-in-class therapy with a long-acting profile that could improve patient compliance and outcomes. We are planning to initiate a phase 2 clinical trial of PRX-115 later this year."

Industry Context

Protalix operates in the specialized biopharmaceutical sector, focusing on rare diseases and conditions like Fabry disease and gout, utilizing its proprietary plant cell-based protein expression system. The company's progress with PRX-115 positions it in the competitive gout treatment market, aiming for a 'best-in-class' therapy. The regulatory challenge for Elfabrio's dosing regimen in Europe highlights the inherent complexities and risks in the rare disease drug approval process, where even approved therapies can face hurdles for label expansions or new formulations. The increased R&D spending aligns with industry trends of continuous innovation and pipeline development to sustain long-term growth.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks.

Stakeholder Impact

• **Shareholders**: Mixed financial results with strong YTD revenue growth and improved net loss, but a Q3 dip and a regulatory setback for Elfabrio's dosing regimen. Pipeline advancement with PRX-115 offers future growth potential.
• **Patients (Fabry Disease)**: The currently approved 1 mg/kg E2W dosing regimen for Elfabrio remains available in the EU, ensuring continued access. The re-examination request for the E4W regimen indicates efforts to provide more convenient treatment options.
• **Patients (Uncontrolled Gout)**: The planned initiation of a Phase 2 trial for PRX-115 offers hope for a potential new, best-in-class, long-acting treatment option.
• **Employees**: Increased R&D expenses, including salary and related expenses, suggest continued investment in personnel for pipeline development.
• **Partners (Chiesi, Pfizer, Fiocruz)**: Continued collaboration on product sales, though quarterly purchase variations impact Protalix's revenue. Chiesi is actively engaged in addressing the Elfabrio regulatory challenge.

Next Steps

• Initiate a Phase 2 clinical trial for PRX-115 for the treatment of uncontrolled gout later this year (2025).
• Continue to incur significant research and development expenses as preclinical and clinical trials advance.
• Await the outcome of the re-examination request by Chiesi Global Rare Diseases regarding the CHMP's negative opinion on Elfabrio's 2 mg/kg E4W dosing regimen.

Key Dates

Recommendation

The company demonstrates solid year-to-date revenue growth and a significant reduction in net loss, indicating improving financial health. The advancement of PRX-115 into Phase 2 is a positive pipeline development with potential for a 'best-in-class' therapy. However, the Q3 revenue and net income decline, coupled with the European regulatory setback for Elfabrio's dosing regimen, introduce near-term uncertainties. The company's cash position is adequate for the next 12 months, but ongoing high R&D expenses and geopolitical risks warrant a cautious approach. A 'hold' recommendation reflects the balance between promising pipeline and YTD performance against quarterly fluctuations and regulatory challenges.

Keywords

Biopharmaceutical, Enzyme Replacement Therapy, Fabry Disease, Gout, PRX-115, Elfabrio, ProCellEx, Clinical Trials, Rare Diseases, SEC Filing, Financial Results, Biotech, Drug Development